Tongyu Lin

Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy

He Huang, Xueying Li, Jun Zhu et al. · JAMA · 2014 · 233 citations

Pharmacy, Oncology, Pharmacotherapy +16

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Yuqin Song, Jianqiu Wu, Xinchuan Chen et al. · Clinical Cancer Research · 2019 · 157 citations

Medicine, Oncology, Pharmacology +17

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matthew J. Matasar, Marcelo Capra, Muhıt Özcan et al. · The Lancet Oncology · 2021 · 137 citations · Full text

Medicine, Immunology, Pharmacology +11

A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma

Chuanliang Cui, Lili Mao, Zhihong Chi et al. · Molecular Therapy · 2013 · 107 citations · Full text

Medicine, Oncology, Pharmacology +12